Associated Papers
Impact of Molecular Evaluations in the Biology, Diagnosis, and Prognostication of Patients With Mastocytosis.
Hoermann G et al.
The Journal of Allergy and Clinical Immunology. in Practice, 2026
Well-differentiated systemic mastocytosis: Genetics, mast cell immunophenotypes, and KIT autophosphorylation.
Schornack BJ et al.
The Journal of Allergy and Clinical Immunology, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Computational modeling of human genetic variants in mice.
Dong K et al.
Biorxiv : the Preprint Server for Biology, 2025
Fedratinib and gandotinib induce apoptosis and enhance the efficacy of tyrosine kinase inhibitors in human mast cells.
Makeeva A et al.
American Journal of Cancer Research, 2025
Establishment and validation of a gene mutation-based risk model for predicting prognosis and therapy response in acute myeloid leukemia.
Liu Y et al.
Heliyon, 2024
Poor Applicability of Currently Available Prognostic Scoring Systems for Prediction of Outcome in KIT D816V-Negative Advanced Systemic Mastocytosis.
Naumann N et al.
Cancers, 2024
Diffuse Cutaneous Mastocytosis: A Current Understanding of a Rare Disease.
Rydz A et al.
International Journal of Molecular Sciences, 2024
KIT V560D-Mutated Systemic Mastocytosis Associated With High-Risk Myelodysplastic Syndrome: A Unique Case of Systemic Mastocytosis-Associated Hematologic Neoplasm.
Medawar G et al.
Case Reports in Hematology, 2024
Diagnosis, Treatment, and Prognosis of Patients with Primary Familial Gastrointestinal Stromal Tumor: A Case Report and Literature Review.
Yan M et al.
The Oncologist, 2023
Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts.
Valent P et al.
International Journal of Molecular Sciences, 2023
Mastocytosis and related entities: a practical roadmap.
Beyens M et al.
Acta Clinica Belgica, 2023
Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management.
Pardanani A
American Journal of Hematology, 2023
KITD816V mutation in blood for the diagnostic screening of systemic mastocytosis and mast cell activation syndromes.
Navarro-Navarro P et al.
Allergy, 2023
Clinicopathological and mutational characteristics of primary double mutant gastrointestinal stromal tumor: a single center study with review of the literature.
Yan J et al.
Bmc Cancer, 2023
Genomics-Driven Precision Medicine in Pediatric Solid Tumors.
Suthapot P et al.
Cancers, 2023
Expanded genetic testing of GIST patients identifies high proportion of non-syndromic patients with germline alterations.
Mandelker D et al.
Npj Precision Oncology, 2023
Molecular and Functional Heterogeneity of Primary Pancreatic Neuroendocrine Tumors and Metastases.
Guo Y et al.
Neuroendocrinology, 2023
A literature review and database of how the primary KIT/PDGFRA variant of a gastrointestinal stromal tumour predicts for sensitivity to imatinib.
Wong NACS et al.
Cancer Genetics, 2022
Mast cell neoplasm: a challenging pathological diagnosis.
Natal RA et al.
Human Pathology, 2022
Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and Update.
El Hussein S et al.
Cancers, 2022
Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis.
González-López O et al.
Cancers, 2022
Broad spectrum of regorafenib activity on mutant KIT and absence of clonal selection in gastrointestinal stromal tumor (GIST): correlative analysis from the GRID trial.
Jeffers M et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2022
Pathogenic and diagnostic relevance of KIT in primary mast cell activation disorders.
Muñoz-González JI et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology, 2021
Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature.
Asselta R et al.
Thoracic Cancer, 2021
Update on Molecular Genetics of Gastrointestinal Stromal Tumors.
Brčić I et al.
Diagnostics (basel, Switzerland), 2021
Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis.
Nedoszytko B et al.
International Journal of Molecular Sciences, 2021
Comprehensive diagnostics of acute myeloid leukemia by whole transcriptome RNA sequencing.
Arindrarto W et al.
Leukemia, 2021
Increased TPSAB1 Copy Number in a Family With Elevated Basal Serum Levels of Tryptase.
Hernández-Hernández L et al.
Frontiers in Medicine, 2021
Systemic Mastocytosis: Molecular Landscape and Implications for Treatment.
Monaldi C et al.
Mediterranean Journal of Hematology and Infectious Diseases, 2021
A Novel Kindred with Familial Gastrointestinal Stromal Tumors Caused by a Rare KIT Germline Mutation (N655K): Clinico-Pathological Presentation and TKI Sensitivity.
Fornasarig M et al.
Journal of Personalized Medicine, 2020
Genotype and phenotype analysis of patients with pediatric cutaneous mastocytosis, especially wild-type KIT patients.
Arase N et al.
The Journal of Dermatology, 2020
Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap.
Piris-Villaespesa M et al.
Frontiers in Pharmacology, 2020
Development and validation of a targeted gene sequencing panel for application to disparate cancers.
McCabe MJ et al.
Scientific Reports, 2019
Well-differentiated systemic mastocytosis with KIT K509I mutation and uterus infiltration in an Asian woman with good response to imatinib.
Zhao DD et al.
Chinese Medical Journal, 2019
The Role of KIT Mutations in Anaphylaxis.
Coulson E et al.
Current Allergy and Asthma Reports, 2019
Finding driver mutations in cancer: Elucidating the role of background mutational processes.
Brown AL et al.
Plos Computational Biology, 2019
Validation of the Oncomine™ focus panel for next-generation sequencing of clinical tumour samples.
Williams HL et al.
Virchows Archiv : an International Journal of Pathology, 2018
Diffuse cutaneous mastocytosis with novel somatic KIT mutation K509I and association with tuberous sclerosis.
Otani IM et al.
Clinical Case Reports, 2018
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
How we diagnose and treat systemic mastocytosis in adults.
Scherber RM et al.
British Journal of Haematology, 2018
Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature.
Alvarez-Twose I et al.
Oncotarget, 2017
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.
Heinrich MC et al.
Jama Oncology, 2017
Familial Gastrointestinal Stromal Tumor with Germline KIT Mutations Accompanying Hereditary Breast and Ovarian Cancer Syndrome.
Sekido Y et al.
Anticancer Research, 2017